Bristol Myers stock has witnessed a stupendous rally in the past six months. We believe there is more room for growth, and ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

There is more to the comparison, and in the sections below, we discuss why we think BMY will outperform JNJ in the next three ...

Shares of Bristol Myers Squibb Co. BMY slid 1.00% to $58.12 Tuesday, on what proved to be an all-around grim trading session ...

Analyst Evan Seigerman of BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of ...

BofA has reinstated coverage of 11 large-cap pharmaceutical and biotech stocks, with Eli Lilly (LLY), Gilead (GILD) and Merck ...

Bristol Myers Squibb has presented data on its cell therapy products at the American Society of Hematology (ASH) Annual ...

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $59.38 which represents a slight increase of $0.54 or 0.92% from the prior close of $58.84. The stock opened at $58.84 and ...

Here is how Compass Therapeutics, Inc. (CMPX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.

Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Multi-Factor Investor model based on the published ...